PATENT CLAIM ANALYSIS

Application Number: 16018496
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

Claim (Index 9):
A method of treating or preventing a neurological or psychiatric disorder, or treating symptoms associated with a neurological or psychiatric disorder, comprising administering to a subject in need thereof an effective amount of a COMT-inhibiting compound in accordance with formula I, or a pharmaceutically acceptable salt thereof: wherein: X is halogen or CF 3 ; Z is SO 2 NR 2 R 3 ; and R 2  and R 3  together form a 3-10 membered monocyclic nitrogen-containing ring system that may be optionally substituted with one or more groups selected from halogen, C\u2261N, CF 3 , OH, C 1 -C 4  alkyl or C 2 -C 4  alkenyl, C 3 -C 6  cycloalkyl, alkoxy, nitro, amino, C 1 -C 4  alkoxycarbonyl, acyl, C 1 -C 4  alkylamino, oxo, SO 2 CH 3 , aryl, aralkyl, heterocyclyl, heteroaryl and heteroarylalkyl.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.23077
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15011353', '15011365', '15458534', '11015348', '14097808']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7816568773116224
- 35 USC 102 Novelty (BERT): 0.5961070597150825
- Combined Prediction Score: 0.7631018955519684
- Mean Citation Score: 363.848216
- Max Citation Score: 524.0887
- Similarity Product: 443.1820296190143

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test